Our commitment is to contribute to the research for new medicines that help improve the understanding of neurological diseases:

1. In the development of genetic studies in collaboration with University of Miami School of Medicine and the San Juan Interamerican University.
   
   
2. In the research for new therapeutic agents for Multiple Sclerosis.

Please refer to some of our research and presentations:

"Clinical features of Multiple Sclerosis in Puerto Rico"

"Low Serum levels of vitamin D in MS patients in Puerto Rico"

"Proteomic Biomarkers of PBMCS from MS patients with vitamin D deficiency"

"HLA en pacientes con esclerosis múltiple en Puerto Rico"

"Clinical Experience with natalizumab in Multiple Sclerosis Center in Puerto Rico"

Please refer to some of our clinical trials in progress:

“Biogen Idec Protocol 101MS402 (TYGRIS) TYSABRI® Global Observational Program in Safety”  

“Biogen Idec Protocol 109MS303-Biogen Idec A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis”  

“Biogen Idec Protocol 101JC402 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri - STRATIFY2”     

“Novartis Protocol CFTY720DUS01 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)”

“Novartis Protocol CFTY720D2403 Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy.”